Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. - Test2 - elhamkhani - TriplyDB

Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

http://www.wikidata.org/entity/Q39317413

about

Echoes of the embryo: using the developmental biology toolkit to study cancer Differentiation and transdifferentiation potentials of cancer stem cells Applications of iPSCs in Cancer Research Autophagy in stem cells.Modelling human disease with pluripotent stem cells Advances and Challenges on Cancer Cells Reprogramming Using Induced Pluripotent Stem Cells Technologies In vitro models of cancer stem cells and clinical applications The reverse control of irreversible biological processes Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology Susceptibility of Human Oral Squamous Cell Carcinoma (OSCC) H103 and H376 cell lines to Retroviral OSKM mediated reprogramming.Detection of lower levels of SNAP25 using multiple microarray systems and its functional significance in medulloblastoma Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.Heterogeneity of osteosarcoma cell lines led to variable responses in reprogramming Lin28B is a novel prognostic marker in gastric adenocarcinoma.Elite model for the generation of induced pluripotent cancer cells (iPCs).FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells Increased expression of Lin28B associates with poor prognosis in patients with oral squamous cell carcinoma Reprogramming of human cancer cells to pluripotency for models of cancer progression Human cancer growth and therapy in immunodeficient mouse models.MicroRNAs Induce Epigenetic Reprogramming and Suppress Malignant Phenotypes of Human Colon Cancer Cells.Mesenchymal to Epithelial Transition Induced by Reprogramming Factors Attenuates the Malignancy of Cancer Cells Aging and reprogramming: a two-way street.Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Tumorigenic potential is restored during differentiation in fusion-reprogrammed cancer cells.Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Role of mesenchymal stem cells in cell life and their signaling.Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.Role of Krüppel-like factors in cancer stem cells.Autophagy in stem and progenitor cells.Patient-derived induced pluripotent stem cells in cancer research and precision oncology.Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells.Reprogramming strategies for the establishment of novel human cancer models.Current status in cancer cell reprogramming and its clinical implications.The cancer paradigms of mammalian regeneration: can mammals regenerate as amphibians?Development of hepatoma-derived, bidirectional oval-like cells as a model to study host interactions with hepatitis C virus during differentiation.SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets.Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response.

P2860

Q26770157-269E3102-300B-42E8-9888-49DF822AA33F Q26782242-C4ABBD93-7EEE-466D-913A-7AA8C9359E70 Q26798036-0A5AB499-6980-47C3-88B3-C403E7426A26 Q26823995-C8C99AF3-04A5-4371-9CB9-099A7F586898 Q26864380-E99C8BEB-E7F1-45AC-9AB0-AF8BFA25C79D Q28071879-F0379C6C-4045-49DB-8C8C-744584D3E4EA Q28076101-95BCDC70-07FB-4EFA-B53E-8DD2388FEFCE Q28077193-1169AC74-01F9-48B4-937A-328EDA962F15 Q28080945-7193DD07-96C6-4749-AF78-C2AB5BB9077B Q33566486-AB995D4D-2596-4418-9C6D-BFD797A13A2D Q33598847-6D1B14B2-30B0-41BD-809C-9955251ABA06 Q33798469-BC616A8C-D4EB-464C-8BEF-D6DD621BD3C8 Q34084254-6158A864-8673-4394-9216-67D6C28F9248 Q34102068-65C08879-B9D4-4B4E-8727-29430DD8F02D Q34121523-76DBC632-55C4-46B2-9A08-BD97576E0836 Q34590216-F5108A76-2831-4E62-BDA7-66A98EE7F7D5 Q34619436-5B263F97-681D-4DB9-B579-B7B11BC8FB8A Q35080717-467D6281-5FEC-46CC-9D74-822276F00325 Q35204997-B9AEC0A4-00F6-458E-B867-43435D66E123 Q35545282-0077E606-E58B-43DE-B200-2520D592099D Q35602071-49D8C58C-5B31-45D7-9DA2-B5BDB61E951B Q36039878-9F0FE4B2-2110-4DA4-AA8F-576DD3360E17 Q36518127-70356B48-53DF-498D-9072-B383BF00E2B6 Q36554387-ED077547-8337-4240-9CA8-AA397C563E92 Q36618624-C27572A3-2F34-4E09-A221-AC5D214E8F72 Q37151483-9C6EA841-6045-4700-939E-87E0A5BE12DA Q37420064-E429DB76-2201-4729-9A65-AFD5389F8DDE Q37589437-DC6C24EC-0645-40D5-87F8-9623D14C41E9 Q38297935-1EA06CBE-9CC2-4A6D-A85D-46BAE038F8F0 Q38330372-279C6395-7A23-467C-99B6-F539622ADDB5 Q38616599-983581A4-CEAF-425E-9E3D-435AA148C05C Q38786566-22F74224-2D5F-4E27-A00B-02EBDAA71467 Q38819957-401E1ECF-659C-4BA7-8E05-71874B075F09 Q38851381-21FDEF72-4169-47AF-AB1B-F4DA13AD0FD4 Q38868126-8F768500-F0D8-41D9-88B7-A4D404C6FEE1 Q38952695-5E96A28A-123D-479E-B911-C6D41D8697BE Q39196150-9827112F-497B-46AD-9C8E-7151A63506BC Q40043190-44CA7798-7064-4991-8AF1-362693754C0B Q40900140-87FCFD96-093D-4EB6-BF08-A3CF63919AC8 Q42038580-0822E550-2E7A-4B65-B0B8-E32879736BFB

P2860

Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming.

http://www.wikidata.org/entity/Q39317413

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Terminal differentiation and l ...... ripotency-based reprogramming.

@en

Terminal differentiation and l ...... ripotency-based reprogramming.

@nl

type

label

Terminal differentiation and l ...... ripotency-based reprogramming.

@en

Terminal differentiation and l ...... ripotency-based reprogramming.

@nl

prefLabel

Terminal differentiation and l ...... ripotency-based reprogramming.

@en

Terminal differentiation and l ...... ripotency-based reprogramming.

@nl

P1433

Q39317413-949151F4-EF8A-41E9-AAB0-7C8B7AA7681D

P1476

Q39317413-DB8B18F3-5CDE-4463-A333-74140A6F40B7

P2093

Q39317413-4D02618B-D4EF-4A55-B59D-3FE1739C3821

Q39317413-7D72CADB-D7B3-4C06-BCBF-A761D966F024

Q39317413-A6C039D4-6FEF-49F3-9BEC-1B2C23986DBC

Q39317413-AA3B86C4-5F5B-4C58-9F73-328993C2B6DC

Q39317413-BBD75CFA-8B0A-481B-86EB-16036591817D

P2860

Q39317413-063AA7C9-19FF-4608-AC22-6CBB68A7FCBB

Q39317413-0BF95D14-3A34-489A-986A-8F883E7DE067

Q39317413-0C6167CB-674C-4EC3-970E-869D9EF6B927

Q39317413-0D5A13A3-A1F7-46DF-B7A4-3E97D7277E4E

Q39317413-0F25A97A-E5EA-4F99-93A2-A425ABCB9717

Q39317413-12433C7E-E3EE-4D4C-8A2D-7AE7064EE23B

Q39317413-13773ACF-C6AB-4368-9919-477DCA3CD2A7

Q39317413-199EB98D-9F7C-44EB-8D6C-1BB7797BB705

Q39317413-1AA0CF1C-2F6B-4138-A6B5-81A43DA0A6DA

Q39317413-1F5999DF-419D-484D-B7BC-E14996DB011E

P2888

Q39317413-11647761-A39D-4DD8-9302-CA7FCE4C465B

P304

Q39317413-7DAFCD8C-DD65-4314-93C4-307EA5CC2255

P31

Q39317413-CF90371F-6708-466D-966D-2F48D3CEC966

P356

Q39317413-3C82B301-E239-4FF4-9B88-FCA8ABB7C3C7

P407

Q39317413-38153B0C-B699-4DFA-9BC7-308719F941F3

P433

Q39317413-A51D187C-29A7-4A43-8DF8-6F4DF09FC007

P478

Q39317413-B0E4F552-CF7F-42DA-A7D0-0BC507BB2DA5

P577

Q39317413-9BA46EC2-92E4-43FF-A43F-421838D5B229

P5875

Q39317413-A840C22A-F943-4ED4-A8A5-490BE3B1A020

P698

Q39317413-8586080F-F174-477D-91B4-C3239177502F

P932

Q39317413-3D8BDBDD-FEDF-4228-AF0C-1013AABCE226

P356

P1433

P1476

Terminal differentiation and l ...... ripotency-based reprogramming.

@en

P2093

F D Cruz

http://www.w3.org/2001/XMLSchema#string

F Remotti

http://www.w3.org/2001/XMLSchema#string

I Matushansky

http://www.w3.org/2001/XMLSchema#string

M Terry

http://www.w3.org/2001/XMLSchema#string

X Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway

Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells

Induced pluripotent stem cell lines derived from human somatic cells

Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

A bivalent chromatin structure marks key developmental genes in embryonic stem cells

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells

The epigenomics of cancer

Promotion of reprogramming to ground state pluripotency by signal inhibition

P2888

P304

2249-60, 2260.e1-21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/ONC.2012.237

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229013075

http://www.w3.org/2001/XMLSchema#string

P698

22777357

http://www.w3.org/2001/XMLSchema#string

P932

3470785

http://www.w3.org/2001/XMLSchema#string